Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions
- PMID: 12913711
- DOI: 10.1097/01.ju.0000081652.31524.27
Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions
Abstract
Purpose: Evidence suggests that unmyelinated C fibers become predominant in the mediation of the detrusor reflex in patients with chronic spinal cord lesions and possibly in idiopathic detrusor hyperactivity. Intravesical vanilloid therapy might be effective in treating refractory detrusor overactivity due to nonspinal cord lesion. This study investigated the clinical effect of intravesical resiniferatoxin in treating detrusor overactivity of nonspinal cord lesions refractory to anticholinergics.
Materials and methods: A total of 41 patients received intravesical resiniferatoxin therapy with 10 ml of 100 nM resiniferatoxin in 10% ethanol solution for 40 minutes. The clinical effects on a decrease in incontinence episodes and urodynamic study were evaluated at baseline and after treatment. Clinical improvement was considered if patients became dry or had a decrease in incontinence episodes of 50%. Therapeutic results were analyzed by disease category and type of initial detrusor response.
Results: Of the 41 patients 10 had neurogenic lesions, 18 had previous transurethral prostatectomy and 13 had idiopathic detrusor overactivity. There were 20 women and 21 men with a mean age of 73.6 years (range 43 to 82) and a symptom duration of 3.6 +/- 4.5 years. After resiniferatoxin treatment 21 patients had clinical improvement (51.2%) including 5 with neurogenic (50%), 11 with previous transurethral prostatectomy (61.1%) and 5 with idiopathic detrusor overactivity (38.5%). An improvement was found in 11 patients with type I initial response (84.6%), 3 patients with type II response (23%) and 7 patients with type III response (46.7%). The 21 patients with improvement had a significant increase in cystometric capacity (208 +/- 80.7 vs 287.2 +/- 118.6 ml, p = 0.001) and a significant decrease in detrusor pressure (33.6 +/- 11.1 vs 27.4 +/- 11.8 cmH(2)O, p = 0.047), but no significant difference in maximal flow rate and residual urine volume.
Conclusions: Intravesical resiniferatoxin was effective in treating refractory detrusor overactivity in 51.2% of patients with nonspinal cord lesions. Patients with detrusor overactivity due to previous bladder outlet obstruction benefited the most. Detrusor contractility decreased after resiniferatoxin treatment in the group with improvement but did not influence voiding efficiency. The initial detrusor response to resiniferatoxin treatment might predict the clinical outcome.
Similar articles
-
Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.J Urol. 2004 Jul;172(1):240-3. doi: 10.1097/01.ju.0000132152.53532.5d. J Urol. 2004. PMID: 15201783 Clinical Trial.
-
Role of C afferent fibers and monitoring of intravesical resiniferatoxin therapy for patients with idiopathic detrusor overactivity.J Urol. 2004 Aug;172(2):596-600. doi: 10.1097/01.ju.0000132769.71014.b5. J Urol. 2004. PMID: 15247740
-
Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.Urology. 2004 May;63(5):868-72. doi: 10.1016/j.urology.2003.12.007. Urology. 2004. PMID: 15134967
-
Refractory neurogenic detrusor overactivity.Int J Clin Pract Suppl. 2006 Dec;(151):22-6. doi: 10.1111/j.1742-1241.2006.01182.x. Int J Clin Pract Suppl. 2006. PMID: 17169007 Review.
-
Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder.J Urol. 1999 Jul;162(1):3-11. doi: 10.1097/00005392-199907000-00002. J Urol. 1999. PMID: 10379728 Review.
Cited by
-
Therapeutic Effect of Botulinum Toxin A on Sensory Bladder Disorders-From Bench to Bedside.Toxins (Basel). 2020 Mar 9;12(3):166. doi: 10.3390/toxins12030166. Toxins (Basel). 2020. PMID: 32182780 Free PMC article. Review.
-
TRPV1 (vanilloid receptor) in the urinary tract: expression, function and clinical applications.Naunyn Schmiedebergs Arch Pharmacol. 2006 Jul;373(4):287-99. doi: 10.1007/s00210-006-0073-2. Epub 2006 May 24. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 16721555 Review.
-
Intravesical resiniferatoxin for the treatment of storage lower urinary tract symptoms in patients with either interstitial cystitis or detrusor overactivity: a meta-analysis.PLoS One. 2013 Dec 20;8(12):e82591. doi: 10.1371/journal.pone.0082591. eCollection 2013. PLoS One. 2013. PMID: 24376550 Free PMC article.
-
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.Int Neurourol J. 2015 Sep;19(3):171-7. doi: 10.5213/inj.2015.19.3.171. Epub 2015 Sep 22. Int Neurourol J. 2015. PMID: 26620899 Free PMC article.
-
Recent advances in the field of urology.Curr Urol Rep. 2006 Jan;7(1):43-9. doi: 10.1007/s11934-006-0037-6. Curr Urol Rep. 2006. PMID: 16480668 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical